IKIldikó Kovács

Ildikó Kovács

*This is an algorithmically generated author record based on publicly available information.

Ildikó Kovács has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Balazs Dome

    Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Translational Medicine, Lund University, Lund, Sweden

    10 shared publications
  • Christian Lang

    Medical University of Vienna 1 Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Austria

    9 shared publications
  • Clemens Aigner

    Department of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria

    9 shared publications
  • Karin Schelch

    Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria

    9 shared publications
  • Kristiina Boettiger

    Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    9 shared publications
  • Zsolt Megyesfalvi

    Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    9 shared publications

Latest Publications

  • Open Access

    Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor models

    by Anna Sólyom-Tisza, Szilvia Török, Yutaka Sugihara, Zsolt Horváth, Áron Gellért, Edina Bugyik, Judit Berta, Ildikó Kovács, Nándor Bárány, György Marko-Varga, et al.

  • Open Access

    Data from Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments

    by Kristiina Boettiger, Ildikó Kovács, Lilla Horvath, Büsra Ernhofer, Karin Schelch, Maria Dorothea Pozonec, Vivien Teglas, Clemens Aigner, Evelyn Megyesfalvi, Ferenc Rényi-Vámos, et al.

    Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.

  • Open Access

    Table S1 from Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments

    by Kristiina Boettiger, Ildikó Kovács, Lilla Horvath, Büsra Ernhofer, Karin Schelch, Maria Dorothea Pozonec, Vivien Teglas, Clemens Aigner, Evelyn Megyesfalvi, Ferenc Rényi-Vámos, et al.

  • Open Access

    Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments

    by Kristiina Boettiger, Ildikó Kovács, Lilla Horvath, Büsra Ernhofer, Karin Schelch, Maria Dorothea Pozonec, Vivien Teglas, Clemens Aigner, Evelyn Megyesfalvi, Ferenc Rényi-Vámos, et al.

    Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.


  • Open Access

    Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Proteomic analysis resulting from the comparison of entinostat sensitive versus resistant cell lines

  • Open Access

    Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Proteomic analysis resulting from the comparison of SCLC cell lines showing synergistic or additive responses to entinostat and cisplatin therapy

  • Open Access

    Supplementary Figures 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

  • Open Access

    Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.

  • Open Access

    Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.

  • Open Access

    Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair

    by Anna Solta, Kristiina Boettiger, Ildikó Kovács, Christian Lang, Zsolt Megyesfalvi, Franziska Ferk, Miroslav Mišík, Konrad Hoetzenecker, Clemens Aigner, Christian R. Kowol, et al.

    Purpose: Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC. Experimental Design: The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays. Results: Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy. Conclusions: In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.